Predilife shares fall to a record low of €0.73 after its financial statements
The stock extends its decline after a half-year report combining sharply higher sales with a very short financing horizon. It sets a new all-time intraday low.
Predilife shares lost 8.75% to €0.73 intraday, compared with €0.80 the previous day, marking an all-time low after breaking the previous record of €0.75, reached on November 2. This €0.75 level is now a resistance, after giving way on the 30-, 150- and 250-session horizons.
The share price is below its 20-day moving average (MM20), a gap of 13.10%, and its 200-day moving average (MM200), a gap of 65.24%, extending a 42.3% decline over three months.
The RSI at 36 remains outside oversold territory, meaning the sell-off has not reached the selling exhaustion that this indicator would signal. The move stands out against a Paris market that is slightly higher, with the CAC 40 gaining 0.31% at midday.
Revenue up 47%, but cash only until February 2027
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Predilife published its first-half 2026 financial statements on November 10. According to the half-year financial statements release, revenue rose from €392,773 to €576,547, and the net loss was reduced. Cash, including certain receivables from the French Treasury, stands at approximately €100k, which provides a financing horizon until February 2027.
The company is under judicial reorganization: the Créteil Commercial Court renewed the six-month observation period at its hearing on November 4, 2026. The growth in sales must therefore be viewed in light of this financing deadline, for a stock that has lost nearly 76% over one year.
Related
SectorServices et infrastructure de santé›Etablissements de santé / EHPAD
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 0,6 millions d'euros
Quarterly revenue: 0,6 millions d'euros
Revenue growth: 46,8 %
Net income: -1,3 millions d'euros
15,1 millions d'euros
Guidance from the release
« La trésorerie à date incluant les créances certaines sur le Trésor Public est d'environ 100k€ ce qui laisse un horizon de trésorerie jusqu'à février 2027. La société fait l'objet d'une procédure de redressement judiciaire dont la période d'observation a été renouvelée pour une durée de 6 mois par le Tribunal de Commerce de Créteil lors de l'audience du 4 novembre 2026. »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
